Advanced search
Publication Cover
Infection and Drug Resistance Volume 15, 2022 - Issue
Submit an article Journal homepage
101
Views
0
CrossRef citations to date
0
Altmetric
CASE REPORT

The Emergence of Resistance Under Firstline INSTI Regimens

Zhiman Xie1 Nanning Infectious Disease Hospital Affiliated to Guangxi Medical University & The Fourth People’s Hospital of Nanning, Nanning, Guangxi, 530023, People’s Republic of ChinaView further author information
,
Jie Zhou2 Guangxi Key Laboratory of AIDS Prevention and Treatment & Guangxi Universities Key Laboratory of Prevention and Control of Highly Prevalent Disease, Nanning, Guangxi, 530021, People’s Republic of China;3 School of Public Health, Guangxi Medical University, Nanning, Guangxi, 530021, People’s Republic of ChinaView further author information
,
Fang Lu2 Guangxi Key Laboratory of AIDS Prevention and Treatment & Guangxi Universities Key Laboratory of Prevention and Control of Highly Prevalent Disease, Nanning, Guangxi, 530021, People’s Republic of China;3 School of Public Health, Guangxi Medical University, Nanning, Guangxi, 530021, People’s Republic of ChinaView further author information
,
Sufang Ai1 Nanning Infectious Disease Hospital Affiliated to Guangxi Medical University & The Fourth People’s Hospital of Nanning, Nanning, Guangxi, 530023, People’s Republic of ChinaView further author information
,
Hao Liang2 Guangxi Key Laboratory of AIDS Prevention and Treatment & Guangxi Universities Key Laboratory of Prevention and Control of Highly Prevalent Disease, Nanning, Guangxi, 530021, People’s Republic of China;3 School of Public Health, Guangxi Medical University, Nanning, Guangxi, 530021, People’s Republic of China;4 Life Science Institute, Guangxi Medical University, Nanning, Guangxi, 530021, People’s Republic of ChinaView further author information
,
Ping Cui2 Guangxi Key Laboratory of AIDS Prevention and Treatment & Guangxi Universities Key Laboratory of Prevention and Control of Highly Prevalent Disease, Nanning, Guangxi, 530021, People’s Republic of China;4 Life Science Institute, Guangxi Medical University, Nanning, Guangxi, 530021, People’s Republic of ChinaView further author information
,
Jianyan Lin1 Nanning Infectious Disease Hospital Affiliated to Guangxi Medical University & The Fourth People’s Hospital of Nanning, Nanning, Guangxi, 530023, People’s Republic of ChinaView further author information
&
Jiegang Huang2 Guangxi Key Laboratory of AIDS Prevention and Treatment & Guangxi Universities Key Laboratory of Prevention and Control of Highly Prevalent Disease, Nanning, Guangxi, 530021, People’s Republic of China;3 School of Public Health, Guangxi Medical University, Nanning, Guangxi, 530021, People’s Republic of ChinaCorrespondence[email protected] [email protected]
ORCID Iconhttps://orcid.org/0000-0003-3271-1694View further author information
ORCID Icon show all
Pages 4269-4274 | Published online: 06 Aug 2022

References

  • Saag MS, Gandhi RT, Hoy JF., et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the international antiviral society-USA panel. JAMA. 2020;324(16):1651–1669. doi:10.1001/jama.2020.17025
  • Society EAC. EACS guidelines (Version 11.1). Available from: https://www.eacsociety.org/media/final2021eacsguidelinesv11.0_oct2021.pdf. Accessed July 27, 2022.
  • Services UDoHaH. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Available from: https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/AdultandAdolescentGL.pdf. Accessed July 27, 2022.
  • Aids, Hepatitis C Professional Group SoIDCMA, Chinese Center for Disease C. [Chinese guidelines for diagnosis and treatment of HIV/AIDS (2021 edition)]. Zhonghua Nei Ke Za Zhi. 2021;60(12):1106–1128. Chinese. doi:10.3760/cma.j.cn112138-20211006-00676
  • Zhao F, Rao M, Chen W, et al. Dolutegravir plus lamivudine dual therapy in treatment naïve HIV-1 patients: preliminary data from real-world. Asia-Pacific AIDS & Co-Infections Conference (APACC); June 17–19; 2021; 29.
  • Dou Y, Li Y, Hong Z, et al. The efficacy of DTG+3TC in naive HIV patients: the real world data from Southern China. 18th European AIDS Conference; October 27–30; 2021; PE2/19.
  • Dou. Y, lv J, Su L, et al. Efficacy of DTG+3TC in naive HIV/AIDS patients with HIV RNA>500,000 copies/mL. Asia-Pacific AIDS & Co-Infections Conference (APACC); June 16–18; 2022; 64.
  • Cahn P, Madero JS, Arribas J, et al. Durable efficacy of dolutegravir (DTG) plus lamivudine (3TC) in antiretroviral treatment-naïve adults with HIV-1 infection – 3-year results from the GEMINI studies. Presented at HIV Glasgow; 2020. Available from: https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-dolutegravir-plus-lamivudine-three-year-data-confirming-long-term-viral-suppression/. Accessed July 27, 2022.
  • Ait-Khaled M, Sierra Madero J, Estrada V, et al. Impact of treatment adherence on efficacy of dolutegravir plus lamivudine and dolutegravir plus tenofovir disoproxil fumarate/emtricitabine: pooled analysis of the GEMINI-1 and GEMINI-2 clinical studies. HIV Res Clin Pract. 2021;16:1–6.
  • Van W, Man CY, Jörg S, et al. Durable efficacy of Two-Drug Regimen (2DR) of Dolutegravir (DTG) plus Lamivudine (3TC) in antiretroviral treatment-naïve adults with HIV-1 infection at 96 weeks: subgroup analyses in the GEMINI studies. Open Forum Infect Dis. 2019;6:45.
  • Rolle CP, Berhe M, Singh T, et al. Dolutegravir/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV. AIDS. 2021;35:1957–1965. doi:10.1097/QAD.0000000000002979
  • Shafer RW. Rationale and uses of a public HIV drug-resistance database. J Infect Dis. 2006;Suppl 194(s1):S51–S58. doi:10.1086/505356
  • Whitcomb JM, Parkin NT, Chappey C, et al. Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. J Infect Dis. 2003;188(7):992–1000. doi:10.1086/378281
  • Fokam J, Takou D, Semengue ENJ, et al. First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens. Antimicrob Resist Infect Control. 2020;9(1):143. doi:10.1186/s13756-020-00799-2
  • Lai J, Liu Y, Han X, et al. Low frequency of integrase inhibitor resistance mutations among therapy-naïve HIV patients in Southeast China. Drug Des Devel Ther. 2021;15:889–894. doi:10.2147/DDDT.S286863
  • Alvarez M, Casas P, de Salazar A, et al. Surveillance of transmitted drug resistance to integrase inhibitors in Spain: implications for clinical practice. J Antimicrob Chemother. 2019;74(6):1693–1700. doi:10.1093/jac/dkz067

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.